Company Profile
Immunocore Holdings plc Stock Price, News & Analysis
- Ticker:
- IMCR
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United Kingdom
Stock performance
34.50 USD (+3.63%)
Close
Last updated: August 6, 2026
1.5B USD
Market cap
Why the stock is moving
Following the latest company update, “Immunocore reports second quarter financial results and provides a business update”, IMCR closed up 3.63% at $34.50 on Aug 6, 2026. The move occurred in the trading session associated with this earnings update.
Company overview
ImmTAX TCR Platform
Immunocore is a commercial-stage biotechnology company developing off-the-shelf bispecific T-cell receptor therapies. Its ImmTAX platform is designed to redirect immune cells against disease-associated targets across oncology, infectious disease and autoimmune disease.
KIMMTRAK Franchise
KIMMTRAK, or tebentafusp, is approved in dozens of countries for HLA-A*02:01-positive unresectable or metastatic uveal melanoma. The therapy is the company’s commercial foundation and the first approved product from its TCR bispecific platform.
Tebentafusp Expansion Programs
Immunocore is testing tebentafusp in the registrational TEBE-AM Phase 3 trial for previously treated advanced cutaneous melanoma. A separate Phase 3 study, ATOM, is evaluating the therapy in high-risk adjuvant uveal melanoma.
PRAME Oncology Portfolio
Brenetafusp is the lead PRAME-targeted ImmTAC and is in the Phase 3 PRISM-MEL-301 trial for first-line advanced cutaneous melanoma, alongside Phase 1/2 work in ovarian and lung cancers. IMC-P115C is a half-life-extended PRAME candidate in Phase 1 development, while IMC-R117C targets PIWIL1 in colorectal and other gastrointestinal cancers.
Infectious Disease Programs
The ImmTAV platform applies TCR bispecifics to virally infected cells. IMC-M113V is in Phase 1/2 development for HIV and is intended to support sustained viral control after patients discontinue antiretroviral therapy.
Autoimmune Expansion
Immunocore’s ImmTAAI molecules are designed to suppress pathogenic T cells selectively within targeted tissue. The initial portfolio includes IMC-S118AI for type 1 diabetes and IMC-U120AI for inflammatory dermatologic disease.
Future catalysts
Completion of enrollment in the TEBE-AM Phase 3 trial expected in the first half of 2026, with topline data possible in the second half of 2026.
Phase 1/2 data for brenetafusp and IMC-P115C expected in the second half of 2026.
Additional Phase 1 multiple-ascending-dose data for IMC-M113V expected in the second half of 2026.
Phase 1 initiation for IMC-S118AI planned in the first half of 2026.
CTA or IND filing for IMC-U120AI planned in the second half of 2026.
Initial clinical data for IMC-R117C expected in 2027.
Recent news
- 01
Immunocore reports second quarter financial results and provides a business update
Source: Immunocore Holdings plc
- 02
Immunocore to report second quarter 2026 financial results and host call on August 6, 2026
Source: Immunocore Holdings plc
- 03
Immunocore presents updated Phase 1 data of brenetafusp in patients with heavily pretreated advanced melanoma
Source: Immunocore Holdings plc
- 04
Immunocore reports first quarter financial results and provides a business update
Source: Immunocore Holdings plc
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Immunocore Holdings plc (IMCR)?
Immunocore Holdings plc (IMCR) most recently closed at 34.50 USD, a +3.63% move versus the previous session.
What is the market cap of Immunocore Holdings plc (IMCR)?
Immunocore Holdings plc currently has a market capitalization of 1.5B USD on BioPharmSignal.
What does Immunocore Holdings plc do?
ImmTAX TCR Platform Immunocore is a commercial-stage biotechnology company developing off-the-shelf bispecific T-cell receptor therapies. Its ImmTAX platform is designed to redirect immune cells against disease-associated targets across oncology, infectious disease and autoimmune disease. KIMMTRAK Franchise KIMMTRAK, or tebentafusp, is approved in dozens of...
On which exchange is IMCR stock listed?
Immunocore Holdings plc (IMCR) is associated with NASDAQ, United Kingdom, Biopharma.
What is HLA-A?
KIMMTRAK Franchise KIMMTRAK, or tebentafusp, is approved in dozens of countries for HLA-A*02:01-positive unresectable or metastatic uveal melanoma.
Which conditions is Immunocore Holdings plc targeting with HLA-A?
Immunocore Holdings plc is associated with oncology, cancer therapeutics, diabetes based on its company overview and current catalyst commentary.
How does Immunocore Holdings plc describe recent progress with HLA-A?
Completion of enrollment in the TEBE-AM Phase 3 trial expected in the first half of 2026, with topline data possible in the second half of 2026. Phase 1/2 data for brenetafusp and IMC-P115C expected in the second half of 2026. Additional Phase 1 multiple-ascending-dose data for IMC-M113V expected in the second half of 2026. Phase 1 initiation for IMC-S118AI...
What is TEBE-AM?
Tebentafusp Expansion Programs Immunocore is testing tebentafusp in the registrational TEBE-AM Phase 3 trial for previously treated advanced cutaneous melanoma.